By: Chris Ryan From: onclive.com The National Institute for Health and Care Excellence (NICE) of the United Kingdom (UK) has recommended the expanded use of the Oncotype DX Breast Recurrence Score® test to guide chemotherapy treatment decisions in postmenopausal women with early-stage, hormone receptor (HR)–positive, HER2-negative breast cancer involving up to 3 positive nodes.1 NICE also confirmed that Oncotype DX could …
NICE approves routine use of drug combination for advanced breast cancer
From: nice.org Another life-extending drug combination for some people with advanced breast cancer will now be available for routine use in the NHS following its approval by NICE in final draft guidance published today (23 September 2022). Palbociclib (also called Ibrance and made by Pfizer) given with fulvestrant, another type of anti-cancer treatment, is recommended for adults with a type …
NICE Approves Adjuvant Trastuzumab for HER2-positive Early Breast Cance
By: Dawn O’Shea From: medscape.com The National Institute for Health and Care Excellence (NICE) has approved trastuzumab emtansine as an option for the adjuvant treatment of human epidermal growth factor receptor 2 (HER2)‑positive early breast cancer in adults who have residual invasive disease in the breast or lymph nodes after neoadjuvant taxane-based and HER2‑targeted therapy. Trastuzumab is an adjuvant …